CITATION REVIEW EXERCISE

  1. Haas NB, Lin X, Manola J, Pins M, Liu G, McDermott D, Nanus D, Heath E,Wilding G, Dutcher J. A phase II trial of doxorubicin and gemcitabine in renalcell carcinoma with sarcomatoid features: ECOG 8802. Med Oncol. 2012Jun;29(2):761-7. doi: 10.1007/s12032-011-9829-8. Epub 2011 Feb 6. PMID:21298497.
  1. Tevaarwerk AJ, Gray RJ, Schneider BP, Smith ML, Wagner LI, Fetting JH,Davidson N, Goldstein LJ, Miller KD, Sparano JA. Survival in patients withmetastatic recurrent breast cancer after adjuvant chemotherapy: Little evidenceof improvement over the past 30 years. Cancer. 2012 Oct 12. doi:10.1002/cncr.27819. [Epub ahead of print] PMID: 23065954.
  1. Flaherty KT, Schiller J, Schuchter LM, Liu G, Tuveson DA, Redlinger M, Lathia C, Xia C, Petrenciuc O, Hingorani SR, Jacobetz MA, Van Belle PA, Elder D, BroseMS, Weber BL, Albertini MR, O'Dwyer PJ. A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel. Clin CancerRes. 2008 Aug 1;14(15):4836-42. doi: 10.1158/1078-0432.CCR-07-4123. PMID: 18676756.
  1. Hoang T, Huang S, Armstrong E, Eickhoff JC, Harari PM. Enhancement ofradiation response with bevacizumab. J ExpClin Cancer Res. 2012 Apr 26;31(1):37.[Epub ahead of print] PMID: 22538017.
  1. Chanan-Khan AA, Niesvizky R, Hohl RJ, Zimmerman TM, Christiansen NP, Schiller GJ, Callander N, Lister J, Oken M, Jagannath S. Phase III randomised study ofdexamethasone with or without oblimersen sodium for patients with advancedmultiple myeloma. Leuk Lymphoma. 2009 Apr;50(4):559-65. doi:10.1080/10428190902748971. PMID: 19373653.
  1. Lera RF, Burkard ME. High Mitotic Activity of Polo-like Kinase 1 Is Requiredfor Chromosome Segregation and Genomic Integrity in Human Epithelial Cells. JBiol Chem. 2012 Dec 14;287(51):42812-25. doi: 10.1074/jbc.M112.412544. Epub 2012 Oct 27. PMID: 23105120.
  1. Bradley KA, Zhou T, McNall-Knapp RY, Jakacki RI, Levy AS, Vezina G, PollackIF. Motexafin-Gadolinium and Involved Field Radiation Therapy for IntrinsicPontine Glioma of Childhood: A Children's Oncology Group Phase 2 Study. Int JRadiatOncolBiol Phys. 2013 Jan 1;85(1):e55-60. doi:10.1016/j.ijrobp.2012.09.004. Epub 2012 Oct 22. PMID: 23092726.
  1. Titz B, Kozak KR, Jeraj R. Computational modelling of anti-angiogenictherapies based on multiparametric molecular imaging data. Phys Med Biol. 2012Oct 7;57(19):6079-101. doi: 10.1088/0031-9155/57/19/6079. Epub 2012 Sep 13.PMID: 22972469.
  1. Adhikarla V, Jeraj R. An imaging-based stochastic model for simulation oftumour vasculature. Phys Med Biol. 2012 Oct 7;57(19):6103-24. doi:10.1088/0031-9155/57/19/6103. Epub 2012 Sep 13. PMID: 22971525.
  1. Argiris A, Kotsakis AP, Hoang T, Worden FP, Savvides P, Gibson MK,Gyanchandani R, Blumenschein GR Jr, Chen HX, Grandis JR, Harari PM, Kies MS, Kim S. Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent ormetastatic squamous cell carcinoma of the head and neck. Ann Oncol. 2013Jan;24(1):220-5. doi: 10.1093/annonc/mds245. Epub 2012 Aug 16.PMID:22898037.
  1. Hu YY, Kwok AC, Jiang W, Taback N, Loggers ET, Ting GV, Lipsitz SR, Weeks JC, Greenberg CC. High-cost imaging in elderly patients with stage IV cancer. J Natl Cancer Inst. 2012 Aug 8;104(15):1164-72. doi:10.1093/jnci/djs286. Epub 2012 Jul 31. PMID: 22851271.
  1. Liu G, Chen YH, Dipaola R, Carducci M, Wilding G. Phase II trial of weeklyixabepilone in men with metastatic castrate-resistant prostate cancer (E3803): a trial of the Eastern Cooperative Oncology Group. ClinGenitourin Cancer. 2012Jun;10(2):99-105. doi: 10.1016/j.clgc.2012.01.009. Epub 2012 Mar 3. PMID: 22386239.
  1. Cashen A, Juckett M, Jumonville A, Litzow M, Flynn PJ, Eckardt J, LaPlant B, Laumann K, Erlichman C, DiPersio J. Phase II study of the histone deacetylaseinhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome(MDS). Ann Hematol. 2012 Jan;91(1):33-8. doi: 10.1007/s00277-011-1240-1. Epub2011 May 3. PMID: 21538061.
  1. Grudzinski JJ, Burnette RR, Weichert JP, Jeraj R. Dosimetric effectiveness oftargeted radionuclide therapy based on a pharmacokinetic landscape. CancerBiotherRadiopharm. 2010 Aug;25(4):417-26. doi:10.1089/cbr.2009.0754. PMID: 20735205.
  1. Smith HA, Cronk RJ, Lang JM, McNeel DG. Expression and immunotherapeutictargeting of the SSX family of cancer-testis antigens in prostate cancer. Cancer Res. 2011 Nov 1;71(21):6785-95. doi: 10.1158/0008-5472.CAN-11-2127. Epub 2011 Aug31. PMID: 21880588.
  1. Watkins Bruner D, James JL, Bryan CJ, Pisansky TM, Rotman M, Corbett T,Speight J, Byhardt R, Sandler H, Bentzen S, Kachnic L, Berk L. Randomized,double-blinded, placebo-controlled crossover trial of treating erectiledysfunction with sildenafil after radiotherapy and short-term androgendeprivation therapy: results of RTOG 0215. J Sex Med. 2011 Apr;8(4):1228-38. doi:10.1111/j.1743-6109.2010.02164.x. Epub 2011 Jan 14. PMID: 21235716.
  1. Bae-Jump VL, Zhou C, Boggess JF, Whang YE, Barroilhet L, Gehrig PA. Rapamycininhibits cell proliferation in type I and type II endometrial carcinomas: asearch for biomarkers of sensitivity to treatment. GynecolOncol. 2010Dec;119(3):579-85. doi: 10.1016/j.ygyno.2010.08.025. Epub 2010 Sep 21. PMID: 20863555.
  1. Watts GS, Futscher BW, Holtan N, Degeest K, Domann FE, Rose SL. DNAmethylation changes in ovarian cancer are cumulative with disease progression andidentify tumor stage. BMC Med Genomics. 2008 Sep 30;1:47. doi:10.1186/1755-8794-1-47. PMID: 18826610.
  1. Ritter MA. Prognostic and predictive markers in radiation therapy: focus onprostate cancer. Cancer Treat Res. 2008;139:97-114. Review. PMID: 18236713.
  1. Tomé WA, Jaradat HA, Nelson IA, Ritter MA, Mehta MP. Helical tomotherapy:image guidance and adaptive dose guidance. Front RadiatTherOncol.2007;40:162-78. Review. PMID: 17641508.